奈达铂治疗晚期非小细胞肺癌临床观察

目的：观察吉西他滨联合奈达铂与联合顺铂方案治疗晚期非小细胞肺癌（NSCLC）的疗效和安全性。方法：60例中晚期非小细胞肺癌患者,其中吉西他滨联合奈达铂化疗方案组（GN组）30例,吉西他滨1000mg/m^2,第1、8天,静脉滴注30分钟,奈达铂80mg/m^2,第2天,滴注时间大于1小时;吉西他滨联合顺铂化疗方案组（GP组）30例,吉西他滨1 000mg/m^2,第1、8天,静脉滴注30分钟,顺铂80-100 mg/m^2,分3d,常规水化利尿。以上2组方案均21天为一个周期。结果：GN组有效率36.67%,GP组有效率40.00%,两组间无显著差异（P〉0.05）;GP组胃肠道反应（80%）发生率明显高于GN组（56.7%）（P〈0.05）;两组肾脏毒性无明显差异;两组白细胞下降发生率分别为56.7%和50.0%,奈达铂组明显（P〉0.05）;血小板下降GN组（73.3%）较GP组（66.7%）显著（P〉0.05）,但无统计学差异。结论：吉西他滨联合奈达铂治疗晚期NSCLC的有效率不低于吉西他滨联合顺铂方案,胃肠道毒性较轻,不良反应主要为骨髓抑制及过敏反应。

Clinical observation of nedaplatin in the treatment of advanced non-small cell lung cancer

Objective：To observe the efficacy and side effects of gemcitabine combined with nedaplatin and cisplatin in the treatment of advanced non-smal cell lung cancer（NSCLC）.Methods：A total of 60 patients with advanced non-small cell lung cancer were divided into the gemcitabine combined with nedaplatin group（group GN,n=30）： Gemcitabine 1 000mg/m^2,d1,8,iv drip;nedaplatin 80mg/m^2,d2,iv drip;And the gemcitabine combined with cisplatin group（group GP,n=30）.Gemcitabine 1 000mg/m^2,d1,8,iv drip;cisplatin80-100 mg/ m^2,divided into three days to iv drip.All patients were undergone 2 cycles,each cycle 21 days.Results： The efficacy of group GN was 36.67% and group GP was 40.00%,there was no significant difference between the two group in curative effect（P〈0.05）.A higher response rate of digestive reaction（80.0%） occurred in group GP,compared to that occurred in group GP（56.7%）,with a significant difference between the two groups（P〈0.05）.There was no significant difference between two groups in the toxicity of kidney.There was a lower incidence of leucopenia response rate（50.0%） in group GP than in group GN（56.7%）,but no significant difference between the groups（P〈0.05）.There was a lower thrombocytopenia response rate（66.7%） in group GP than in group GN（73.3%）,but no significant difference between the groups（P〈0.05）.Conclusion：There is no significant difference between gemcitabine combined with cisplatin group and nedaplain group in the effect and there is a lower digestive reaction than cisplatin group.the main adverse reaction was myelosuppression and allergic reaction,in the treatment of NSCLC.